Search

This article discusses three cases of patients who developed cytokine release syndrome (CRS) during treatment for various conditions. The first case involves a 59-year-old man with diffuse large B-cell lymphoma who experienced CRS after receiving tisagenlecleucel. Despite treatment with various medications, his condition did not improve until he was given anakinra. The second case involves a 71-year-old woman with follicular lymphoma who developed CRS after receiving axicabtagene ciloleucel. She was treated with dexamethasone and tocilizumab. The third case involves a 15-year-old boy with relapsed B-cell acute lymphoblastic leukemia who experienced CRS after receiving tisagenlecleucel. Despite initial treatment with paracetamol and hydrocortisone, his condition worsened and he was eventually treated with tocilizumab. [Extracted from the article]

A study reported a case of cytokine release syndrome (CRS) in a patient with refractory diffuse large B-cell lymphoma (DLBCL) who was treated with lisocabtagene-maraleucel. The patient experienced grade 3 CRS, but the duration of treatment and outcome were not specified. The study included a total of 20 patients treated between September 2021 and March 2022, but no further details about these patients were provided. [Extracted from the article]

A study reported a case of cytokine release syndrome (CRS) in a patient with refractory diffuse large B-cell lymphoma (DLBCL) who was treated with lisocabtagene-maraleucel. The patient experienced grade 3 CRS, but the duration of treatment and outcome were not specified. The study included 20 patients treated between September 2021 and March 2022, but no further details about the other patients were provided. [Extracted from the article]

A 25-year-old man with diffuse large B-cell lymphoma (DLBCL) developed chylothorax, a condition characterized by the accumulation of lymphatic fluid in the chest cavity, as a result of cytokine release syndrome (CRS) during treatment with welgenaleucel. The patient had a history of various treatments for DLBCL, including surgery, chemotherapy, and radiation. After receiving welgenaleucel, he experienced symptoms such as fatigue, diarrhea, and high fever, and was diagnosed with grade 3 CRS. Treatment with tocilizumab, a medication that targets IL-6, led to significant improvement in his symptoms. The patient was discharged in stable condition and achieved complete remission of DLBCL. The CRS and chylothorax were determined to be a result of welgenaleucel treatment. [Extracted from the article]

A 39-year-old man experienced grade 2 mucositis and grade 2 cytokine release syndrome (CRS) while being treated for diffuse large B-cell lymphoma with relmacabtagene-autoleucel. He also had a lack of efficacy with various other treatments for follicular lymphoma and diffuse large B-cell lymphoma. Despite these complications, he eventually achieved complete metabolic remission after receiving relmacabtagene-autoleucel and maintenance therapy with ibrutinib. [Extracted from the article]